**ORIGINAL ARTICLE - : FUNCTIONAL NEUROSURGERY - MOVEMENT DISORDERS** 



# The effects of chronic subthalamic stimulation on nonmotor symptoms in advanced Parkinson's disease, revealed by an online questionnaire program

Minako Kawaguchi<sup>1</sup> • Kazuhiro Samura<sup>2</sup> • Yasushi Miyagi<sup>3</sup> • Tsuyoshi Okamoto<sup>4</sup> • Ryo Yamasaki<sup>5</sup> • Nobutaka Sakae<sup>5,6</sup> • Fumiaki Yoshida<sup>7</sup> • Koji lihara<sup>1</sup>

Received: 12 July 2019 / Accepted: 12 December 2019 / Published online: 2 January 2020 © Springer-Verlag GmbH Austria, part of Springer Nature 2020

### Abstract

**Background** This study was designed to detect and assess the frequency and severity of nonmotor symptoms (NMSs) in advanced Parkinson's disease (PD) and to investigate the effects of subthalamic nucleus deep brain stimulation (STN-DBS) on NMSs.

**Methods** We developed an online PC-based questionnaire program to assess NMSs in PD. Twenty-six PD patients who underwent bilateral STN-DBS were assessed. The NMS questionnaire consisted of 54 NMSs in three categories, based on Witjas et al. (2002). For each NMS, the patients were asked whether or not it was present, whether or not the fluctuating manifestations correlated with the timing of levodopa-induced motor fluctuations, and how severe the NMS was. Patients were assessed by this system before surgery and at the follow-up visit, 3 to 6 months after surgery. At the postoperative assessment, patients were also assessed on preoperative NMSs using recall.

**Results** The most frequent preoperative NMSs were constipation and visual disorders, while the most frequent postoperative NMSs were difficulty in memorizing and pollakiuria. The ranking of most frequent NMSs changed from before to after surgery. NMSs of drenching sweats, dysphagia, and constipation were significantly ameliorated, while NMSs of dyspnea and slowness of thinking were significantly deteriorated after surgery. The preoperative assessment by postoperative recall gave very different results from that of the preoperative assessment.

**Conclusion** An online questionnaire system to assess NMSs in patients with advanced PD suggested that STN-DBS might influence the frequencies of some kinds of NMSs.

Keywords Subthalamic nucleus · Deep brain stimulation · Questionnaire program · Nonmotor symptoms · Parkinson's disease

This article is part of the Topical Collection on *Functional Neurosurgery* -Movement disorders

Kazuhiro Samura samura@iuhw.ac.jp

- <sup>1</sup> Department of Neurosurgery, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- <sup>2</sup> Department of Neurosurgery, School of Medicine, International University of Health and Welfare, 4-3, Kozunomori, Narita, Chiba 286-8686, Japan
- <sup>3</sup> Department of Stereotactic and Functional Neurosurgery, Medical Co. LTA Fukuoka Mirai Hospital, Fukuoka, Japan

- <sup>4</sup> Faculty of Arts and Science, Kyushu University, Fukuoka, Japan
- <sup>5</sup> Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- <sup>6</sup> Department of Neurology, National Hospital Organization Omuta National Hospital, Fukuoka, Japan
- <sup>7</sup> Department of Anatomy & Physiology, Faculty of Medicine, Saga University, Saga, Japan

### Introduction

Parkinson's disease (PD) is one of the most common neurodegenerative disorders, with a prevalence generally estimated at 0.3% of the population in industrialized countries [7]. It is the second most common neurodegenerative disorder after Alzheimer's disease, and its prevalence increases with age, reaching 1% in people over 60 years of age [7]. One of the main pathological features of PD is the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc), which gives rise to the four major motor symptoms of this disease: bradykinesia, tremor at rest, rigidity, and postural instability [8].

There are also many nonmotor symptoms (NMSs) that are common features of PD [11], such as dysautonomic, psychiatric and cognitive, and sensory symptoms [28, 29]. These problems, together with the chronic and progressive nature of the illness itself, may seriously hamper patients' physical and mental health [6]. Similar to the motor symptoms of PD, NMSs significantly disable daily activity and negatively affect quality of life in PD patients. Some NMSs are alleviated by dopaminergic treatment. Subthalamic nucleus deep brain stimulation (STN-DBS) is a well-established surgical option for motor symptoms in PD patients [15]. This surgery dramatically alleviates the cardinal motor symptoms and allows for a reduction in antiparkinsonian drugs. There are some previous reports about the effects of STN-DBS on NMSs. In a study by Witjas et al. [29], STN-DBS was effective against NMSs such as drenching sweats, anxiety, fatigue, akathisia, and slowness of thinking. However, a rapid development of extreme apathy or abulia shortly after surgery was also described, especially in patients with very high doses of dopaminergic drugs that were drastically reduced after surgery [14]. Transient confusion has also been observed in some patients, possibly as a result of the long duration of brain surgery and the withdrawal of dopaminergic drugs [18]. In another study, night sleep was reported to improve in all patients [20]. However, because there are many types of NMSs, it can be very difficult to categorize and evaluate these types of symptoms. Some NMSs are subjective only, and other NMSs may be influenced by the effects of either STN-DBS or medication levels. To detect and evaluate NMSs in PD patients, we developed an online questionnaire system for NMSs. Compared with other reports of NMSs, this study is novel in that the questionnaire was conducted to investigate not only the presence and severity of symptoms, but also the onset of symptoms. An online system is useful because the acquired data can be categorized and anonymized, and multiple researchers can then use the data simultaneously. We used this system when speech-language-hearing therapists (STs) performed higher brain function tests both before


and after surgery, and assessed the changing NMSs in PD patients after STN-DBS.

### Methods and materials

We used the questionnaire proposed by Witjas et al. [28] because this classification includes many NMSs in detail in each category, and we wanted to cover as many NMSs as possible in our study. The NMS questionnaire consisted of 54 NMSs in three categories (26 dysautonomic, 21 psychiatric/cognitive, and 7 sensory symptoms), and was used with some modifications to adapt the questionnaire to the Japanese language. For the patients' comfort, the questionnaire was completed during "on-time" (on-drug condition preoperatively, and onstimulation and on-drug conditions postoperatively). The initial postoperative DBS programming in all patients was performed using unipolar stimulation of the contact located at the dorsal STN. The stimulation parameters were reevaluated and adjusted as required during hospital visits to achieve maximal therapeutic effect against Parkinson's disease symptoms.

The questionnaire program was administrated on a PC to reduce the burden on patients and raters, to shorten the interview time, and to ensure the same questionnaire for all symptoms. The questionnaire program ran on a web browser and had graphical interfaces (Fig. 1). The patients were able to select the answer of the question by clicking on it, and their data were encrypted and password-locked to protect personal data. Figure 1 a shows the start page. On the second page (Fig. 1b), for each NMS, patients were asked if the symptom was present or absent. On the third page (Fig. 1c), for each NMS, patients were asked whether the fluctuating manifestations were correlated with the timing of "just before on-drug" ("just before on-time"), "on-drug" ("on-time"), "just before offdrug" ("just before off-time"), "off-drug" ("off-time"), "dyskinetic state," or "unrelated to either on- or off-drug" ("on/offunrelated time"). Before the questionnaire began, the definitions of "on," "off," and "dyskinetic state" were explained to patients. At the end of each NMS questionnaire (Fig. 1d), the patients were asked to rate the severity of each NMS with a scale ranging from 0 to 4 (0: no discomfort, 1: slight, 2: moderate, 3: marked, 4: maximum disability).

Twenty-six PD patients (seven men and nineteen women) who underwent bilateral STN-DBS in Kyushu University Hospital between June 2006 and May 2010 were assessed by this program. All patients were assessed before and after surgery and gave written informed consent for the collection and publication of their data. All experimental procedures were approved by the Ethics Committee of the Kyushu University Hospital. Inclusion criteria were responsiveness to levodopa and disabling motor fluctuations and/or levodopa-induced dyskinesia that was refractory to the adjustment of antiparkinsonian medication. Exclusion criteria were atypical parkinsonism,



**Fig. 1** The online questionnaire program system. The questionnaire program was administrated on a PC and ran on a web browser. It had graphical interfaces, and patients were able to select the answer to the question by clicking on it. **a** Start page. **b** Second page: the patients were asked if each NMS was present or absent. **c** Third page: for each NMS, the patients were asked whether the fluctuating manifestations correlated

noticeable brain atrophy, age (> 75 years), dementia (MMSE < 20), or unstable psychiatric impairments. Subjects underwent contemporaneous bilateral STN-DBS implantation using MRIguided indirect targeting and a multitrack microrecording method [32]. Using our online questionnaire, we investigated which symptoms were ranked highest before and after surgery, and the changes in severity of each NMS. The severity of symptoms in each parameter was evaluated using five levels (from 0 to 4) both before surgery and at 3 to 6 months after surgery. Statistical analysis was performed using a Wilcoxon signedrank test to determine the relative difference between the preoperative and postoperative states. We used correlation coefficients and regression analysis to measure the strengths of the relationships between LEDD reduction after surgery and symptom improvement or worsening. P values < 0.05 were considered significant. We interpreted correlation coefficient sizes as follows:  $0.0 \le |r| < 0.2$ : almost no correlation;  $0.2 \le |r| < 0.4$ :

with the timing of "just before on-drug" ("just before on-time"), "ondrug" ("on-time"), "just before off-drug" ("just before off-time"), "offdrug" ("off-time"), "dyskinetic state," or not with motor symptoms ("on/ off-unrelated time"). **d** Last page: the patients were asked to rate the severity of each NMS on a scale ranging from 0 to 4 (0: no discomfort, 1: slight, 2: moderate, 3: marked, 4: maximum disability

weak correlation;  $0.4 \le |r| < 0.7$ : moderately strong correlation; and  $0.7 \le |r| \le 1.0$ : strong correlation. At the postoperative examination, patients were asked to recall which symptoms existed before surgery. In the recall study, one case was excluded because of insufficient data (n = 25). Patients also completed the unified Parkinson's disease rating scale (UPDRS) with activity of daily living score (UPDRS part II) and motor score (UPDRS part III), and the Mini-Mental State Examination (MMSE), both before and after surgery. The levodopaequivalent daily dose (LEDD) was calculated according to the conversion formula proposed by Tomlinson et al. [26]

### Results

Mean patient age was 61.9 years, mean age at disease onset was 48.3 years, and mean disease duration was 13.7 years.

The maximum age of the patients was 74 years and the lowest MMSE score was 21. The mean interview duration was 20 min. Using an online questionnaire program, all patients were able to answer questions without any problems. Table 1 summarizes patient profiles and surgical outcomes. All patients had some NMSs. After surgery, UPDRS part II and III scores in "off-time" significantly improved by 64% and 74%, respectively (p < 0.01). In addition, the LEDD and LDD (levodopa daily dose) were significantly reduced by 59.3% and 70.0%, respectively (p < 0.01). Table 2 gives the ten most frequent NMSs. Preoperatively, the most frequent NMSs were constipation (88%), visual disorders (69%), flatulence (65%), and difficulty in memorizing (65%), which all fall into the categories of dysautonomic or psychiatric and cognitive symptoms. Postoperatively, the most frequent NMSs were difficulty in memorizing (58%), pollakiuria (46%), visual disorders (42%), oral dryness (38%), flatulence (38%), anxiety (38%), irritability (38%), and slowness of thinking (38%). These also fall into the categories of dysautonomic or psychiatric and cognitive symptoms. There were no sensory symptoms in the top 10 most frequent preoperative and postoperative NMSs.

Next, we investigated the changes in severity of each NMS after surgery in the "off-time" and "on/off-unrelated time." NMSs in the "just before on-time," "on-time," "just before off-time," and "dyskinetic state" were excluded because they were very rarely reported. The NMSs that were ameliorated or deteriorated in the postoperative state were examined further. Tables 3, 4, and 5 show the *p*-values for postoperative changes in severity in three categories (Table 3: dysautonomic symptoms; Table 4:

**Table 1**Patient profile (male = 7: female = 19)

Characteristics	Mean $\pm$ SD	
Age (y)	$61.9 \pm 9.3$	
Disease onset (y)	$48.3\pm10.9$	
Disease duration (y)	$13.7\pm6.1$	
	Preop	Postop
	Mean $\pm$ SD	$Mean\pm SD$
UPDRS II (on)	$10.2 \pm 7.2$	$7.0\pm7.4$
UPDRS II (off)	23.5 ±9.1	$8.4 \pm 7.4$
UPDRS III (on)	$14.6\pm10.2$	$9.2\pm9.3$
UPDRS III (off)	$41.3\pm18.7$	$10.8\pm8.6$
Hoehn & Yahr stage (on)	$2.5 \pm 1.0$	$2.6 \pm 1.0$
Hoehn & Yahr stage (off)	$3.8\pm 0.9$	$2.6 \pm 1.0$
LEDD (mg/day)	$762.8\pm384.4$	$310.5\pm160.0$
LDD (mg/day)	$456.9\pm205.0$	$138.5\pm135.1$
MMSE	$27.2\pm2.5$	$26.7\pm3.4$

*UPDRS* Unified Parkinson's Disease Rating Scale, *LEDD* levodopaequivalent daily dose, *LDD* levodopa daily dose, *MMSE* Mini-Mental State Examination

 Table 2
 The ten most frequent nonmotor symptoms in preoperative and postoperative state.

Order	Symptom	Category	Frequency (%)
Preop			
1	Constipation	D	88
2	Visual disorders	D	69
3	Flatulence	D	65
3	Difficulty in memorizing	P	65
5	Oral dryness	D	62
6	Pollakiuria	D	58
6	Anxiety	P	58
8	Irritability	P	58 54
o 9	•	P D	34 46
-	Urinary urgency	D P	46 46
9	Slowness of thinking	Р	46
Posto	þ		
1	Difficulty in memorizing	Р	58
2	Pollakiuria	D	46
3	Visual disorders	D	42
4	Oral dryness	D	38
4	Flatulence	D	38
4	Anxiety	Р	38
4	Irritability	Р	38
4	Slowness of thinking	P	38
8	Mutism	Р	35
9	Constipation	D	31
9	Urinary urgency	D	31

(Values are percentages)

D dysautonomic symptoms, P psychiatric and cognitive symptoms

psychiatric and cognitive symptoms; Table 5: sensory symptoms). In the dysautonomic symptom category in Table 3, drenching sweats (p = 0.026) and dysphagia (p = 0.031) during "off-time," and constipation (p =0.010) during "on/off-unrelated time," were ameliorated following STN-DBS. In contrast, dyspnea (p = 0.032) during "on/off-unrelated time" was deteriorated postoperatively. For psychiatric and cognitive symptoms (Table 4), only slowness of thinking (p = 0.029) was significantly deteriorated during "on/off-unrelated time." No sensory symptoms showed significant changes between preoperative and postoperative states (Table 5). From the correlation analysis between LEDD reduction after surgery and the improvement or worsening of symptoms, "dysphagia" was weakly correlated with LEDD reduction after surgery, but this result did not reach statistical significance (r = 0.384, p = 0.052). No other symptoms showed any correlation with LEDD reduction after surgery.

**Table 3** The p values ofpostoperative change in severityof dysautonomic symptoms

Ameliorated		Dysautonomic symptoms	Deteriorated	
Off-time	On/off-unrelated time		Off-time	On/off-unrelated time
0.026*	0.785	Drenching sweats		
0.346		Sensation of being hot		0.268
	0.272	Facial flushing	0.346	
0.719		Oral dryness		
		Dyspnea	0.858	0.032*
0.031*		Dysphagia		0.066
	0.010*	Constipation	0.174	
0.129		Distal cold sensations		
0.850		Excessive salivation		0.524
		Urinary urgency	0.672	1.000
		Visual disorders	0.410	0.916
		Palpitation		0.507
0.789		Abdominal bloating		
0.346		Dysuria		
		Precordialgia		1.000
	0.847	Flatulence	0.789	
0.346	0.586	Stridor		
		Facial pallor	1.000	
0.371		Abdominal pain		0.269
		Paroxysmal hunger		1.000
0.586		Pollakiuria		0.247
	0.495	Pyrosis	0.181	
	1.000	Nausea	1.000	
0.789	0.943	Leg edema		
	0.480	Belching		
1.000	0.660	Coughing		

\*p value < 0.05

Table 6 shows the reported preoperative NMSs before and after surgery. Table 6 (A) gives the 10 most frequent preoperative NMSs by recall after surgery, while Table 6 (B) shows the top 10 preoperative NMSs that the patients stated they did not have when asked to recall preoperative NMSs after surgery. Pollakiuria (36%), flatulence (32%), facial flushing (28%), and constipation (28%) were the top-ranked symptoms in Table 6 (B). Moreover, many dysautonomic NMSs were ranked highly. Table 6 (C) shows the top 10 NMSs that the patients reported as preoperative symptoms by recall after surgery, but that they did not report before surgery. Drenching sweats (32%), fatigue (32%), akathisia (32%), and mental hyperactivity (28%) were ranked top in Table 6 (C). Some sensory and psychiatric and cognitive symptoms were ranked highly here, as well as dysautonomic symptoms. Importantly, the results were quite different depending on the time of evaluation; that is, preoperative NMSs reported by recall after surgery were quite different from the preoperative NMSs that were reported prior to surgery.

### Discussion

Regarding the development of an online questionnaire program for NMSs, two points should be noted. The first point is that recall is not reliable; our results were quite different depending on the timing of the evaluation. Reporting of NMSs in PD is easily influenced by feelings at the timing of the questionnaire. In Table 6, the preoperative NMSs are completely different from those that were recalled postoperatively. It is therefore impossible to obtain accurate results if patients are not assessed preoperatively. The second point is that a long examination time might exhaust patients [12]. Our interview system addressed this point by enabling us to relatively easily evaluate NMSs in PD patients with minimum stress for the subjects involved. However, because the preoperative questionnaire was completed during "on-time," the "on" medication state might have meant that patients were more optimistic (or hypomanic), and this may have affected or compromised the subjective evaluation of NMSs.

 
 Table 4
 The p values of postoperative change in severity of psychiatric/cognitive symptoms

Ameliorated		Psychiatric/cognitive symptoms	Deteriorated	
Off-time	On/off-unrelated time		Off-time	On/off-unrelated time
0.850		Anxiety		0.602
0.432		Fatigue		
0.494		Irritability		0.177
		Hallucinations	1.000	0.904
		Self-withdrawal	1.000	0.437
0.773		Euphoria		0.824
0.892		Lassitude/weariness		0.494
		Sadness		1.000
0.797		Hyperactivity		0.666
1.000		Sensation of imminent death		
0.304		Abulia		0.098
		Mutism	0.429	0.060
0.526	1.000	Panic attack		
		Aggressive behavior	1.000	0.345
		Sensation of injustice	1.000	0.572
	0.710	Sexual disorders		
		Guilty feelings	1.000	0.854
0.463		Slowness of thinking		0.029*
0.914		Difficulty in memorizing		0.056
		Mental emptiness	0.914	0.168
		Mental hyperactivity		0.669

\*p value < 0.05

Several questionnaires have been developed for the assessment of NMSs observed in PD, including the nonmotor symptom scale (NMSS) [4], NMSQuest [3, 19], and PDQ-39 [21]. Our questionnaire system had a graphical interface, meaning that even older patients and hearing-impaired patients could operate the program, and the mean duration for the interview was only 20 min. In the present study, STs used this system to efficiently assess NMSs, but we believe that accurate test results can be obtained even if this system is used by clinicians and other medical staff who do not regularly perform this kind of questionnaire. There is, however, one potential problem when considering the generalization of this questionnaire: the meaning of words may change depending on the language that is used. Translating questions into different languages may affect the results of the study. Although we referred to Witjas et al. [28, 29] in this study, it may not have always been possible to ask questions with exactly the same nuances, because we did not verify the back translations of the questions. It is therefore not appropriate to directly compare the results of the current study with the results of studies by Witjas et al.

With regard to the results from the present study, there is also a possibility that STN-DBS influences NMSs. In Table 2, there is a difference between the highest ranked NMSs before and after surgery. There are two possible factors that may influence changes in NMSs after an STN-DBS operation. One is that STN-DBS directly influences NMSs, and the other is that the reduction in LEDD, caused by the positive effects of STN-DBS on motor symptoms, has a modulatory effect on NMSs. The aforementioned reports suggest that STN-DBS affects some parts of NMSs, but it is not clear whether symptom changes are a direct or indirect effect of chronic stimulation of the STN. Our study had similar findings to a previous study by Witjas [29] in that the most frequent preoperative NMSs were anxiety, slowness of thinking, and irritability, and that many dysautonomic NMSs, especially drenching sweats, were markedly improved by STN-DBS. In addition, to ensure the reliability of results, it was necessary to ask patients to evaluate their symptoms at the present time, and not to recall symptoms that existed at a previous time point.

In the current study, drenching sweats and dysphagia during "off-time" and constipation during "on/off-unrelated time" were ameliorated following STN-DBS, and dyspnea and slowness of thinking were significantly deteriorated postoperatively during "on/off-unrelated time." Using correlation analysis, no symptoms were significantly correlated with postoperative LEDD reduction; **Table 5** The *p* values ofpostoperative change in severityof sensory symptoms

Ameliorated		Sensory symptoms	Deteriorated	
Off-time	On/off-unrelated time		Off-time	On/off-unrelated time
0.177		Akathisia		0.172
		Tightening sensation		0.174
0.134		Tingling sensation		0.414
0.072		Diffuse pain		1.000
0.854		Restlessness		0.189
0.394		Neuralgic pain		0.099
	1.000	Burning sensation		

\*p value < 0.05

however, the low number of patients in the present study may have affected these results. Constipation was one of the most common preoperative symptoms, reported in 88% of patients before surgery, but just 31% of patients reported this symptom after surgery (Table 2). There are three possibilities to explain the amelioration of constipation in the current study. The first possibility involves the postoperative LEDD reduction that occurs as a result of STN-DBS. Zibetti et al. first suggested this mechanism [33]. Dopaminergic medications are known to influence anorectal function, with an improvement in manometric and electromyographic measures of anorectal function during "on" periods and a deterioration during "off" episodes [2]. The second possibility to explain the improvement in constipation is that STN-DBS has a direct effect on extrapyramidal motor dysfunction. For example, Abott et al. [1] suggested that increased colonic transit time may be a manifestation of the same processes that cause the motor symptoms of PD. The third possibility relates to the increase in physical activity of PD patients after STN-DBS. Studies focusing on the general population and on older patients have shown that immobility or insufficient physical activity is linked to constipation [9, 24]. An amelioration of motor symptoms in PD patients after surgery might improve their mobility and physical activity levels, thus improving their constipation. For these reasons, STN-DBS might improve constipation both directly and indirectly. Drenching sweats were also reported by more than 87% of preoperative patients [25, 28]. Krack et al. reported that the alleviation of drenching sweats after STN-DBS is because of stimulation of the descending sympathetic fibers in the zona incerta [14], while Witjas et al. [29] reported that this alleviation is probably due to STN-DBS-induced improvements in motor complications. Although the relationship between drenching sweats and dyskinesia was not clear in our study, STN-DBS treatment resulted in a significant improvement of drenching sweats. Dysphagia during "off-time" was also significantly improved in the present study. Although clinically

significant improvements in swallowing function were not identified in one previous report [27], many reports have shown functional improvement in the tongue, pharynx, and larynx after STN-DBS [5, 13, 16, 17, 23, 31, 33]; therefore, STN-DBS may be related to the improvement in this symptom.

Because dyspnea and slowness of thinking deteriorated postoperatively during "on/off-unrelated time" in the present study, these symptoms may be affected not only by stimulation parameters but also by other factors such as drug treatment or disease progression. The effect of STN-DBS on dyspnea has not been previously reported and requires further clinical study. Regarding slowness of thinking, there are reports that cognitive tasks that rely on working memory are ameliorated by STN-DBS, whereas performance in other cognitive tasks is deteriorated [10, 22]. STN-DBS did not reduce overall cognition, but there was a selective postoperative decrease in frontal cognitive functions [30]. However, because slowness of thinking is a subjective symptom, it may be difficult to identify the damaged subfunction in detail and to understand how it affects patients' quality of life.

There are several important possible outcomes from the results of this study. If it becomes clear how STN-DBS affects NMSs, a new research field may be developed that pursues the physiological and pathological mechanisms of the interactions between brain stimulation and systemic responses that are derived from peripheral autonomic nerves or other nonmotor neural networks. In addition, the effect of DBS methodology, such as proximity to limbic part of STN, caudate involvement in lead trajectory, and stimulation frequencies may be explored. There is also a possibility that drug reduction methods will be able to be customized depending on individual patients and their specific NMSs. In addition, information about possible worsening or amelioration of NMSs can be disclosed to patients who are considering DBS and other device-aided therapies.

**Study limitations** This study has some limitations. Because only a small number of patients were included in this study,

**Table 6** The ten most frequent reported preoperative NMSs before and after surgery (n = 25)

Order	Symptom	Category	Frequency (%)			
(A) Preoperative NMSs by recall after surgery						
1	Oral dryness	D	64			
1	Constipation	D	64			
3	Difficulty in memorizing	Р	60			
3	Akathisia	S	60			
5	Urinary urgency	D	56			
5	Visual disorders	D	56			
7	Fatigue	Р	52			
7	Mutism	Р	52			
7	Mental hyperactivity	Р	52			
10	Excessive salivation	D	48			

(B) Preoperative NMSs that the patients stated they did not have when asked to recall preoperative NMSs after surgery

1	Pollakiuria	D	36
2	Flatulence	D	32
3	Facial flushing	D	28
3	Constipation	D	28
5	Visual disorders	D	24
5	Palpitations	D	24
7	Anxiety	Р	24
8	Irritability	Р	20
8	Hallucinations	Р	20
8	Lassitude/weariness	Р	20

#### (C) Preoperative NMSs that the patients reported as preoperative symptoms by recall after surgery but did not report before surgery

Junpt	in a set of the set of	a not report	cercie saig
1	Drenching sweats	D	32
1	Fatigue	Р	32
1	Akathisia	S	32
4	Mental hyperactivity	Р	28
5	Excessive salivation	D	24
5	Urinary urgency	D	24
7	Distal cold sensations	D	20
7	Mutism	Р	20
9	Sensation of being hot	D	16
9	Oral dryness	D	16
9	Dyspnea	D	16
9	Abdominal bloating	D	16
9	Hyperactivity	Р	16
9	Sensation of imminent death	Р	16
9	Neuralgic pain	S	16

*NMSs* nonmotor symptoms, *D* dysautonomic symptoms, *P* psychiatric and cognitive symptoms, *S* sensory symptoms

the statistical power was low. We must also acknowledge that this questionnaire program only states a preliminary measurement, and that it is difficult to test the reliability and construct validity of this questionnaire program because there were a limited number of cases available.

# Conclusion

We presented an online questionnaire system for NMSs in patients with advanced PD. This interview system enabled us to evaluate NMSs in PD patients easily, in detail, and with minimum stress for patients. With this program, comprehensive test results can be obtained not only by STs but also by people who are not used to performing desk inspections. It should be noted that STN-DBS affects not only motor symptoms but also some NMSs. Questionnaire studies should be performed at the time that symptoms are present, because answer by recall is not reliable.

**Acknowledgments** We thank Bronwen Gardner, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

### **Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** This study was conducted in accordance with the Declaration of Helsinki. This study design was approved by the Ethics Committee of Kyushu University (30-388).

**Informed consent** Informed consent was obtained from all individual participants included in the study.

## References

- Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW (2001) Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57:456–462
- Ashraf W, Wszolek ZK, Pfeiffer RF, Normand M, Maurer K, Srb F, Edwards LL, Quigley EM (1995) Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Mov Disord 10:650–657
- 3. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 21:916–923
- 4. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 22:1901–1911

- Cronin-Golomb A (2013) Emergence of nonmotor symptoms as the focus of research and treatment of Parkinson's disease: introduction to the special section on nonmotor dysfunctions in Parkinson's disease. Behav Neurosci 127:135–138
- de Lau LML, Breteler MMB (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5:525–535
- 8. Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46(Suppl 1):S30–S33
- Dukas L, Willett WC, Giovannucci EL (2003) Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women. Am J Gastroenterol 98:1790–1796
- Jahanshahi M, Ardouin CM, Brown RG, Rothwell JC, Obeso J, Albanese A, Rodriguez-Oroz MC, Moro E, Benabid AL, Pollak P, Limousin-Dowsey P (2000) The impact of deep brain stimulation on executive function in Parkinson's disease. Brain. 123:1142– 1154
- Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368–376
- Katsarou Z, Bostantjopoulou S, Peto V, Kafantari A, Apostolidou E, Peitsidou E (2004) Assessing quality of life in Parkinson's disease: can a short-form questionnaire be useful? Mov Disord 19: 308–312
- Kitashima A, Umemoto G, Tsuboi Y, Higuchi MA, Baba Y, Kikuta T (2013) Effects of subthalamic nucleus deep brain stimulation on the swallowing function of patients with Parkinson's disease. Parkinsonism Relat Disord 19:480–482
- Krack P, Fraix V, Mendes A, Benabid AL, Pollak P (2002) Postoperative management of subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 17(Suppl 3):S188–S197 Review
- Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349:1925–1934
- Kulneff L, Sundstedt S, Olofsson K, van Doorn J, Linder J, Nordh E, Blomstedt P (2013) Deep brain stimulation - effects on swallowing function in Parkinson's disease. Acta Neurol Scand 127:329–336
- Lengerer S, Kipping J, Rommel N, Weiss D, Breit S, Gasser T, Plewnia C, Krüger R, Wächter T (2012) Deep-brain-stimulation does not impair deglutition in Parkinson's disease. Parkinsonism Relat Disord 18:847–853
- Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 339: 1105–1111
- Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR (2007) Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629
- Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A (1999) Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53:85–90
- Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 4: 241–248

- 22. Pillon B, Ardouin C, Damier P, Krack P, Houeto JL, Klinger H, Bonnet AM, Pollak P, Benabid AL, Agid Y (2000) Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology. 55:411–418
- Silbergleit AK, LeWitt P, Junn F, Schultz LR, Collins D, Beardsley T, Hubert M, Trosch R, Schwalb JM (2012) Comparison of dysphagia before and after deep brain stimulation in Parkinson's disease. Mov Disord 27:1763–1768
- Södergren M, McNaughton SA, Salmon J, Ball K, Crawford DA (2012) Associations between fruit and vegetable intake, leisuretime physical activity, sitting time and self-rated health among older adults: cross-sectional data from the WELL study. BMC Public Health 12:551
- Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N (2003) Sweating dysfunction in Parkinson's disease. Mov Disord 18:1459–1463
- Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25:2649–2653
- Troche MS, Brandimore AE, Foote KD, Okun MS (2013) Swallowing and deep brain stimulation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 19:783–788
- Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Chérif AA (2002) Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59:408– 413
- Witjas T, Kaphan E, Régis J, Jouve E, Chérif AA, Péragut JC, Azulay JP (2007) Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 22: 1729–1734
- Witt K, Pulkowski U, Herzog J, Lorenz D, Hamel W, Deuschl G, Krack P (2004) Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Arch Neurol 61:697–700
- Wolz M, Hauschild J, Koy J, Fauser M, Klingelhöfer L, Schackert G, Reichmann H, Storch A (2012) Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord 18:994–997
- Yoshida F, Miyagi Y, Morioka T, Hashiguchi K, Murakami N, Matsumoto K, Nagata S, Sasaki T (2008) Assessment of contact location in subthalamic stimulation for Parkinson's disease by coregistration of computed tomography images. Stereotact Funct Neurosurg 86:162–166
- 33. Zibetti M, Torre E, Cinquepalmi A, Rosso M, Ducati A, Bergamasco B, Lanotte M, Lopiano L (2007) Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol 58:218–223

#### Comments

This is a very practical work showing how the internet can be used to ease the fulfilment of clinical questionnaires. Although some issues related to the self-administration of tests still hold, it improves the easiness to obtain preoperative data at the preoperative stage, and highlights the possible bias of retrieving preoperative data postoperatively.

Juan Barcia Madrid, Spain

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.